A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Debt-to-Equity or its related term are showing as below:
MEX:LABB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.47 Med: 0.67 Max: 0.95
Current: 0.69
During the past 13 years, the highest Debt-to-Equity Ratio of Genomma Lab InternacionalB de CV was 0.95. The lowest was 0.47. And the median was 0.67.
MEX:LABB's Debt-to-Equity is ranked worse than 78.49% of 809
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs MEX:LABB: 0.69
Genomma Lab InternacionalB de CV (MEX:LABB) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Genomma Lab InternacionalB de CV Debt-to-Equity Related Terms
Genomma Lab InternacionalB de CV Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Debt-to-Equity Chart
MEX:LABB vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a Debt-to-Equity of 0.69 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is near median its historical median of 0.67. Over the past decade, Genomma Lab InternacionalB de CV's Debt-to-Equity has ranged from 0.47 to 0.95. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #635 out of 809 companies in the Drug Manufacturers industry, placing it in the top 78.5%.
Is Genomma Lab InternacionalB de CV's Debt-to-Equity too high?
Genomma Lab InternacionalB de CV's current Debt-to-Equity of 0.69 is near median its 10-year median of 0.67. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 0.95. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Genomma Lab InternacionalB de CV's value of 0.69 is 155.6% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #635 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #635 out of 809 companies for Debt-to-Equity. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Genomma Lab InternacionalB de CV's value of 0.69 is 155.6% above this benchmark. Historically, Genomma Lab InternacionalB de CV's own Debt-to-Equity has ranged from 0.47 to 0.95 over the past decade. While the company's 10-year median is 0.67 vs. the industry median of 0.27, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Debt-to-Equity of 0.69 is 155.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Debt-to-Equity is 0.69, which is near median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.66, compared to a current price of MXN15.23 — trading 13.8% below its estimated fair value. The current Debt-to-Equity is 0.69, which is near median its 10-year median of 0.67 and 155.6% above the Drug Manufacturers industry median of 0.27. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Debt-to-Equity is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.23 is trading 13.8% below its estimated GF Value™ of MXN17.66.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Debt-to-Equity: 0.69 (near median its 10-year median of 0.67)
GF Value™: MXN17.66 vs. price of MXN15.23 (13.8% below fair value)
Industry Position: 155.6% above the Drug Manufacturers median (#635 of 809)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
